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pressure, pulse, cutaneous, nasoocular, or pulmonary reactions were monitored until 4
hours after the procedure. Pts were followed-up for 18.1± 6.3 months. Major adverse
cardiac events (MACE), defined as death, repeat revascularization and stroke were
recorded.
Results: The desensitization procedure was successful in 71 pts (92.2%). No serious
adverse reactions occurred: 3 pts with history of idiopathic urticaria developed
cutaneous reaction, 2 pts (with frequent asthma attacks) experienced shortness of breath
associated with bronchospasm, and 1 pt had shortness of breath without bronchospasm.
All reactions were immediately resolved with corticosteroids and antihistamines. The
mean time from desensitization to coronary angiography was 35.6±33.3 hours. All pts
but 15 (19.4%) underwent PCI (1.8 stent/pt, DES 75.5%, multivessel PCI 31.4%) and
were discharged on dual antiplatelet therapy. At follow-up, aspirin was maintained in
92.9% pts. None of the discontinuations were due to allergic reaction. The incidence
of MACE was 6.5% (1 non-cardiac death and 4 repeat revascularizations). None of
the pts experienced stent thrombosis.
Conclusion: This novel desensitization procedure seems to be safe and effective in
the vast majority of pts with cutaneous or respiratory aspirin sensitivity. Complex PCI
procedures can be performed also in such pts, without increasing the risk of stent
thrombosis.
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Background: The Resolute stent (R-ZES) is a new-generation zotarolimus-eluting
stent that utilizes the BioLinx polymer, a proprietary tri-polymer coating that provides
gradual drug elution out to 180 days while maintaining biocompatibility to allow for
neointimal healing. The RESOLUTE International study showed optimal 1-year
performance of the R-ZES for treatment of coronary artery disease, however, longer
follow-up is required for a full comprehension of its clinical safety and efficacy.
Methods: RESOLUTE International is part of the Global RESOLUTE Clinical Trial
Program, and is a prospective, multi-center, observational registry, which enrolled 2349
patients with symptomatic coronary artery disease from 88 centers worldwide. The
trial had minimal eligibility criteria to reflect routine clinical practice, and the primary
endpoint was cardiac death and target-vessel myocardial infarction (CD/TV-MI) at 1
year. This trial was harmonized with the rest of the Global RESOLUTE Clinical
Program from an adjudication point of view. Enhanced edit checks to detect unreported
procedural MIs; and full monitoring of all patient consents and 25% monitoring of
patient source files were also per performed. We will report the overall 2-year clinical
outcomes, and comparisons between unmonitored (75%) and source file monitored
(25%) patient cohorts.
Results: Patients were enrolled between 29 August 2008 and 19 March 2009, and
97.4% of patients completed 1-yr follow-up. At baseline, 78% were male, 31% had
diabetes mellitus, 46% with acute coronary syndrome, and 67.5% had at least 1
complex clinical/lesion characteristic. . Clinical outcomes at 1 year were; CD/TV-MI,
4.2%; TLR, 3.4%; and definite/probable ST, 0.9%. There were no significant
differences in 1-year outcomes between monitored and unmonitored patients, reflecting
the robustness of the trial data.
Conclusion: We will report the overall 2-year clinical outcomes with special emphasis
on safety endpoints at the time of the meeting.
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Background: Randomized trials comparing outcomes after implantation of first
generation drug-eluting stents (DES) versus second generation DESs in patients with
acute coronary syndromes (ACS) are limited. In this substudy of the SORT OUT IV
trial, we compared the clinical outcome among patients with ACS and stable angina
pectoris (SAP) treated with everolimus-eluting stents (EES) or sirolimus-eluting stents
(SES).
Methods: Of 2,705 patients treated for ACS or SAP, 1,178 (43.5%) patients had ACS
and were treated with EES (n=1,353, ACS: n=580) or SES (n=1,352, ACS: n=598).
The primary composite endpoint, major adverse cardiac events (MACE), was defined
as a composite of cardiac death, myocardial infarction (MI), stent thrombosis, or target
vessel revascularization (TVR) within 18 months.
Results: 18-month MACE was higher among ACS patients compared to patients with
SAP: 8.1% vs. 6.7%, Hazard Ratio (HR) 1.23, 95 % confidence interval (CI) 0.93-
1.62. In ACS patients, clinical outcome in EES treated patients did not differ
significantly to SES treated patients at 18 months; MACE 7.3% vs. 8.9% (HR 0.81,
95% CI 0.54-1.22), cardiac death 2.8% vs. 2.0% (HR 1.39, 95% CI 0.66-2.93), MI
2.1% vs. 2.3% (HR 0.88, 95% CI 0.41-1.91), stent thrombosis 0.5% vs. 0.7% (HR
0.77, 95% CI 0.17-3.45) and TVR 4.3% vs. 5.9%, (HR 0.73, 95% CI 0.44-1.22). Also
in patients with SAP, the clinical outcome did not differ significantly between EES-
and SES-treated patients.
Conclusion: EES and SES appear similar with respect to MACE in patients with ACS.
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Background: Nobori drug eluting stent (DES) is coated only abluminally with a matrix
of drug Biolimus A9 and polymer degradable within 1 year. We explored the safety
benefit of the DES after full polymer degradation particularly in high risk patient
populations.
Methods: NOBORI2 study enrolled 3067 consecutive patients in 125 centers in
Europe and Asia treated with Nobori DES. Patients were assigned to one of the pre-
specified groups: On-label and Off-label groups. The Off-label group was composed
of patients mainly outside of the indications proven in pivotal trials. Primary endpoint
was target lesion failure (TLF), a composite of cardiac death, MI and target lesion
revascularization (TLR) at 1 year. Data are monitored through electronic database and
on-site. All adverse events are adjudicated by an independent clinical event committee
and an independent corelab analyzes angiographic images.
Results: In this real-world population 73% of patients were treated for Off-label
indications. The most frequent Off-label indications were acute coronary syndrome
(65%), bifurcation stenting (26%), occlusion (12%), restenosis (9%) and saphenous
vein graft (2%). Patients in Off-label use were more frequently male, had higher
incidence of moderate to severe renal impairment and history of MI. Lesions in Off-
label group were more complex, more frequently ostial, thrombotic and calcified
(p<0.005). At 2 year follow-up 94.7% of patients were contacted; the TLF rate was
5.9% (132 pts) in Off-label group and 2.8% (23 pts) in On-label group (p<0.001). In
Off-label group 1.9% of patients died of cardiac cause, 2.7% suffered MI and 2.4%
underwent re-PCI of the target lesion. In On-label group 0.7% of patients died, 1.5%
suffered MI and 0.6% underwent re-PCI of the target lesion. Stent thrombosis rate was
0.9% in Off- and 0.6% in On-label treated patients (p=NS).
Conclusion: Low rates of TLF and late stent thrombosis at 2 years follow-up for
patients treated for Off-Label indications are very encouraging. They further indicate
the potential benefit of Nobori DES even for treatment of challenging lesions and high-
risk patients with coronary artery disease.
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Background: We used the Swedish angiography and angioplasty registry (SCAAR)
to investigate occurrence and results of treatment of in - stent restenosis (ISR) in
coronary stents.
Methods: We evaluated clinically driven results of treatment of ISR in a very large
patient cohort of all consecutive coronary stent implantations in Sweden between
January 1, 2005 and October 06, 2010. The data were analyzed with regard to different
types of treatment, patient and stenosis characteristics. 142678 stents were implanted
during the time period, of these 9031 were implanted in ISR at 7134 procedures in
6191 patients.
Results: 1. Through the years 2005 (4.3%) till 2010 (6.1%) occurrence of PCI - treated
ISR has not decreased. 2. Direct DES - stenting shows a reported re - restenosis rate
of 3.8 % at 1 year. Also with DEB - therapy the rate at 1 year was low (4.8 %) but on
a still low number of patients. Re – restenosis rate after direct BMS – stenting (7.4 %)
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